Adial Pharmaceuticals shares rise 19.56% premarket after U.S. Senate supports expanded clinical trial endpoints beyond abstinence in alcohol and substance use disorder treatments.

Adial Pharmaceuticals Inc. surged 19.56% in premarket trading following the U.S. Senate’s endorsement of expanded clinical trial endpoints for alcohol and substance use disorder treatments. The development is seen as a positive catalyst for the company, which focuses on therapies for these conditions, as broader endpoints could enhance the likelihood of regulatory approval by allowing more flexible outcome measures in trials. The announcement, made on August 20, signals growing legislative support for innovative treatment approaches, reinforcing investor confidence in Adial’s pipeline and long-term growth potential.